Alternatives for Ovulation Induction and Superovulation: Serms and Aromatase Inhibitors

By David E. Tourgeman MD, F.A.C.O.G.

Ovulatory dysfunction is one of the most common causes for reproductive difficulty in otherwise fertile couples. Once successful ovulation is achieved, fertility is often restored. For many years, the first line of pharmacologic ovulation induction to treat infertility has involved the use of selective estrogen receptor modulators (SERMs), of which clomiphene citrate (Clomid) has been most extensively studied. The first trial of Clomid resulted in successful ovulation induction in approximately 80% of women, and ultimately half were able to achieve pregnancy. The use of Clomid for superovulation in patients with unexplained infertility, has also been the mainstay when coupled with intrauterine insemination, IUI. Yet despite advances in ultrasonographic technology, hormone assays, and urinary leutinizing hormone kits, success with Clomid has not changed dramatically. Therefore, it is important that we evaluate our options for ovulation induction and superovulation.

SERMs for Infertility Treatment

SERMs are structurally diverse non-steroidal compounds (triphenylethlene derivatives) that bind to estrogen receptors and have tissue-dependent agonistic and antagonistic effects. Clomid is characterized by agonistic properties when endogenous estrogen levels are low, and as a competitive antagonist when levels are high. In anovulatory women, depletion of estrogen receptors in the hypothalamus results in normalization of gonadotropin releasing hormone (GnRH) secretion and hence, secretion of pituitary follicle stimulating hormone (FSH) levels are optimized. This in turn will drive ovarian follicular development, resulting in ovulation.

The goal in anovulatory women is mono-ovulation, whereas with superovulation multiple follicle development is desired. However, even in anovulatory women, the use of Clomid can result in the development of multiple follicles as the result of prolonged clearance of its isomers. Thus, the risk of multiple gestation is increased to 8%. Other side effects also limit the usefulness of Clomid Namely; Clomid exerts undesirable anti-estrogenic effects in the periphery (endocervix, endometrium, and ovary) that helps explain the discrepancy between ovulation and conception rates. Additionally, vasomotor flushes may occur as frequently as in 10% of cycles. Other side effects include mood swings, visual disturbances, breast tenderness, pelvic discomfort, and nausea.

The use of tamoxifen (TMX), another SERM, for ovulation induction has been the subject of clinical investigation since the early 1970s. A recent prospective randomized controlled trial compared the efficacy of TMX with Clomid in anovulatory women. The overall rates of ovulation and pregnancy were similar in both groups. Other studies have suggested that TMX may be superior to Clomid in that there does not appear to have an adverse impact on the endometrium. TMX has been shown to be effective in the treatment of ovulation induction even when Clomid has failed, but has yet to be tested for superovulation.

Raloxifene, a structurally related compound, also appears to increase follicular phase FSH, with resultant elevation in estradiol levels. However, it has not been evaluated as a potential ovulation induction agent. In addition, raloxifene may act primarily as an antagonist at the level of the endometrium.

Other novel uses of the SERMs have included the combination of Clomid and TMX. Their combined effects in the treatment of anovulation appears to result in increased ovulation rates and pregnancy. Although the combination of Clomid and human menopausal gonadotropins induces ovulation in anovulatory, patients undergoing IVF, and those who have had a poor response to gonadotropins alone, the combination of the newer SERMs and human menopausal gonadotropins remains largely uninvestigated.

Aromatase Inhibitors- Drugs for Infertility Treatment

Aromatase inhibitors are unique pharmacologic agents whose main mode of action is to decrease peripheral estradiol production by the ovary. This is in contrast to the SERMs that act centrally, nonetheless the end result is similar; namely, a decrease in central estrogen feedback that stimulates a compensatory increase in pituitary gonadotropin release. By reducing circulating estradiol levels, aromatase inhibitors have been used to treat endometriosis, estrogen responsive cancers, leiomyomata uteri, as well as to induce ovulation. Primate studies have demonstrated that administration of aromatase inhibitors during the follicular phase results in the development of mature follicles which, when coupled with hCG could be shown to ovulate.

Summary

In women with anovulatory infertility, the treatment of first choice for induction of ovulation is most commonly Clomid. However, not all women will ovulate with Clomid alone or may have impaired endometrial development. Yet others may have severe side effects limiting the use of Clomid. In these patients, the use of other SERMs such as tamoxifen may allow the achievement of our goals. Yet, the impact of multiple gestation continues to reduce the appeal of these medications. With our growing experience, aromatase inhibitors may help a Clomid accomplish mono-ovulation in this group of patients. In couples with unexplained infertility that are undergoing superovulation and intrauterine insemination, it appears that the SERMs are most effective in provoking the development of multiple follicles, and thus remain our primary treatment modality.

Download Full Text Article with References